Company Overview and News

 
Weekly Review: Master Limited Partnership CEFs - So Many 'BUY' Opportunities

2018-09-19 seekingalpha
Over the past few months, most of you have noticed our increased activity in closed-end funds as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us.
SMM ENI.UN FEI

 
Weekly Review: Master Limited Partnership CEFs

2018-08-22 seekingalpha
Over the past few months, most of you have noticed our increased activity in closed-end funds as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us.
SMM NDP

 
SMM / Salient Midstream & MLP Fund FORM N-PX

2018-08-17 sec.gov
Form N-PX UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-PX
SMM

 
Weekly Review: Master Limited Partnership CEFs

2018-08-16 seekingalpha
Over the past few months, most of you have noticed our increased activity in closed-end funds as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us.
SMM NDP

 
SMM / Salient Midstream & MLP Fund DEF 14A

2018-08-15 sec.gov
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
SMM

 
SMM / Salient Midstream & MLP Fund N-CSRS

2018-08-03 sec.gov
N-CSRS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-CSR
SMM

 
Weekly Review: Master Limited Partnership CEFs

2018-07-25 seekingalpha
Over the past few months, most of you have noticed our increased activity in closed-end funds as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us.
SMM JMLP NDP

 
Weekly Review: Master Limited Partnership CEFs

2018-07-19 seekingalpha
Over the past few months, most of you have noticed our increased activity in closed-end funds as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us.
SMM FMO JMLP NDP

 
Weekly Review: Master Limited Partnership CEFs

2018-07-11 seekingalpha
Over the past few months, most of you have noticed our increased activity in closed-end funds as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us.
FEN SMM TYG NTG ENI.UN SRF JMLP CEM FEI NDP KYN

 
Weekly Review: Master Limited Partnership CEFs

2018-07-05 seekingalpha
Over the past few months, most of you have noticed our increased activity in closed-end funds as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us.
FEN GMZ SMM TYG JMLP

2
Weekly Review: Master Limited Partnership CEFs

2018-06-27 seekingalpha
Over the past few months, most of you have noticed our increased activity in closed-end funds as the inflow of volatility finally shook them up and created various arbitrage, and directional, opportunities for active traders such as us.
FEN GMZ SMM JMLP

2
SMM / Salient Midstream & MLP Fund 40-17G

2018-05-04 sec.gov
40-17G FEDERAL INSURANCE COMPANY
SMM

2
SMM / Salient Midstream & MLP Fund FORM N-Q (Quarterly Schedule of Portfolio Holdings)

2018-04-27 sec.gov
Form N-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q
SMM

2
March: CEF Declines Better Than S&P 500, But Opportunities Arise

2018-03-30 seekingalpha
Market volatility may remain, but CEFs provide an opportunity to get income and exposure while waiting for the correction to end.
GGT SMM EVF IF KYN ECCB FPL ECCA FMO ECC JMLP ECCZ NMI RQI KED ECCY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to SMM / Salient Midstream & MLP Fund on message board site Silicon Investor.

Stratcomm Media, Ltd., (otc bb: SMMM) Stratcomm Media, Ltd., (otc bb: SMMM) Stratcomm Media, Ltd., (otc bb: SMMM) SMM on TSE - Simmonds Capital SMM on TSE - Simmonds Capital SMM on TSE - Simmonds Capital
Summit Design (SMMT)-Another EPIC? Summit Design (SMMT)-Another EPIC? Summit Design (SMMT)-Another EPIC? Simmonds Technoligies SMM/TSE Simmonds Technoligies SMM/TSE Simmonds Technoligies SMM/TSE
CUSIP: 590188108